Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lyell Immunopharma
Biotech
Death drives Lyell to take 2-track approach to dose escalation
Lyell is holding back dose escalation in people with lung metastases while racing ahead in the wider solid tumor population.
Nick Paul Taylor
Jun 26, 2024 10:00am
Lyell loses 25% of staff, CMO to conserve cash post-GSK collab
Nov 8, 2023 7:41am
EMD Serono taps new COO—Chutes & Ladders
Jul 7, 2023 9:30am
GSK pays out £30M to Adaptimmune as cell therapy work ends
Apr 11, 2023 11:47am
Roche's executive dominoes continue to tip—Chutes & Ladders
Dec 16, 2022 9:30am
GSK severs Immatics partnership in further T-cell retreat
Nov 17, 2022 11:00am
